[go: up one dir, main page]

MX2022009839A - Gm-csf de accion prolongada y metodos de uso. - Google Patents

Gm-csf de accion prolongada y metodos de uso.

Info

Publication number
MX2022009839A
MX2022009839A MX2022009839A MX2022009839A MX2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A
Authority
MX
Mexico
Prior art keywords
csf
acting
methods
long
peptides
Prior art date
Application number
MX2022009839A
Other languages
English (en)
Inventor
Feng Wang
Weijun Shen
Peter Schultz
Sean Joseph
Lei Lei
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022009839A publication Critical patent/MX2022009839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Materials For Medical Uses (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En este documento se describen péptidos del factor estimulante de colonias de granulocitos y macrófagos (GM-CSF) y composiciones que comprenden péptidos de GM-CSF. Estas moléculas pueden ser útiles para el tratamiento de enfermedades o afecciones neurológicas.
MX2022009839A 2020-02-12 2021-02-11 Gm-csf de accion prolongada y metodos de uso. MX2022009839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020074834 2020-02-12
PCT/US2021/017684 WO2021163346A2 (en) 2020-02-12 2021-02-11 Long-acting gm-csf and methods of use

Publications (1)

Publication Number Publication Date
MX2022009839A true MX2022009839A (es) 2022-09-05

Family

ID=77295183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009839A MX2022009839A (es) 2020-02-12 2021-02-11 Gm-csf de accion prolongada y metodos de uso.

Country Status (10)

Country Link
US (1) US20230116380A1 (es)
EP (1) EP4103618A4 (es)
JP (1) JP2023514972A (es)
KR (1) KR20220141315A (es)
CN (1) CN115461374A (es)
AU (1) AU2021220865A1 (es)
CA (1) CA3170128A1 (es)
IL (1) IL295122A (es)
MX (1) MX2022009839A (es)
WO (1) WO2021163346A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN111593044A (zh) * 2019-02-20 2020-08-28 成都医学院 一种胶红酵母固定化细胞及其应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
CN118660715A (zh) * 2022-02-11 2024-09-17 合作伙伴治疗有限公司 用于神经退行性或神经系统疾病或病症的基于粒细胞-巨噬细胞集落刺激因子的治疗
CA3247715A1 (en) * 2022-04-08 2023-10-12 Partner Therapeutics, Inc. PROLONGED-ACTING STIMULATION FACTOR FOR GRANULOCYTE AND MACROPHAGE COLONIES
WO2024108050A1 (en) * 2022-11-16 2024-05-23 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
KR100740972B1 (ko) * 2004-07-12 2007-07-20 인하대학교 산학협력단 Ｇｍ－ｃｓｆ를 유효성분으로 함유하는 신경질환 치료제
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN102807619B (zh) * 2011-06-03 2016-08-03 北京韩美药品有限公司 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物
KR102361237B1 (ko) * 2013-07-11 2022-02-09 더 스크립스 리서치 인스티튜트 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP4011919A3 (en) * 2015-12-09 2022-10-12 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use

Also Published As

Publication number Publication date
US20230116380A1 (en) 2023-04-13
WO2021163346A3 (en) 2021-09-23
CN115461374A (zh) 2022-12-09
CA3170128A1 (en) 2021-08-19
JP2023514972A (ja) 2023-04-12
KR20220141315A (ko) 2022-10-19
EP4103618A4 (en) 2024-05-01
AU2021220865A1 (en) 2022-09-01
EP4103618A2 (en) 2022-12-21
WO2021163346A2 (en) 2021-08-19
IL295122A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MX2022009839A (es) Gm-csf de accion prolongada y metodos de uso.
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
MX2022004513A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
WO2022165362A3 (en) Epigenetic gene regulation to treat neurological diseases and pain
EP3761970A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
AU2003294388A1 (en) 1, 2, 3- triazole amide derivatives as cytokine inhibitors
MX2025005878A (es) Inhibidores de ripk2 y usos de los mismos
EP4520326A3 (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
EP4301417A4 (en) TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES
WO2024023262A3 (en) Nucleic acid compounds
WO2021226439A3 (en) Engineered relaxins and methods of use thereof
CA3242855A1 (en) Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders
MX2025001060A (es) Degradación de proteínas dirigida de parp14 para usar en terapia.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EP4138852A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
MX2025001068A (es) Derivados arilos tricíclicos, y composiciones y métodos de los mismos
MX2024010401A (es) Quiméricos dirigido a proteólisis (protac) de proteína de translocación del linfoma del tejido linfoide asociado a las mucosas 1 (malt1)
EP4017873A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH
WO2024086692A3 (en) Herpesvirus-induced gene or protein expression and methods for treating neurological disorders
WO2024163641A3 (en) Formulations for treating cancer